Get started
Paradigm Biopharmaceuticals Ltd.Paradigm Biopharmaceuticals Ltd.Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd.

No trades
OverviewFinancialsNewsCommunityTechnicalsSeasonalsETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪93.76 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.0327 USD
Net income (FY)
‪−12.34 M‬ USD
Revenue (FY)
‪34.27 K‬ USD
Shares float
‪372.69 M‬
Beta (1Y)
2.80

About Paradigm Biopharmaceuticals Ltd.


Sector
Health Technology
Industry
Pharmaceuticals: Generic
CEO
Paul John Rennie
Website
paradigmbiopharma.com
Headquarters
Melbourne
Founded
2014
IPO date
Aug 19, 2015
Identifiers
2
ISIN AU000000PAR5
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.

Check out other big names from the same industry as PBIGF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


DACE
Dimensional Australian Core Equity Trust Units
Weight
0.00%
Market value
‪47.89 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of PBIGF is 0.2300 USD — it has increased by 2.45% in the past 24 hours. Watch Paradigm Biopharmaceuticals Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Paradigm Biopharmaceuticals Ltd. stocks are traded under the ticker PBIGF.
PBIGF stock has risen by 2.45% compared to the previous week, the month change is a −8.00% fall, over the last year Paradigm Biopharmaceuticals Ltd. has showed a −36.11% decrease.
PBIGF reached its all-time high on Feb 4, 2020 with the price of 3.0000 USD, and its all-time low was 0.1147 USD and was reached on Oct 1, 2024. View more price dynamics on PBIGF chart.
See other stocks reaching their highest and lowest prices.
PBIGF stock is 2.39% volatile and has beta coefficient of 2.80. Track Paradigm Biopharmaceuticals Ltd. stock price on the chart and check out the list of the most volatile stocks — is Paradigm Biopharmaceuticals Ltd. there?
Today Paradigm Biopharmaceuticals Ltd. has the market capitalization of ‪93.76 M‬, it has increased by 1.00% over the last week.
Yes, you can track Paradigm Biopharmaceuticals Ltd. financials in yearly and quarterly reports right on TradingView.
Paradigm Biopharmaceuticals Ltd. is going to release the next earnings report on Feb 25, 2026. Keep track of upcoming events with our Earnings Calendar.
PBIGF net income for the last half-year is ‪−8.45 M‬ USD, while the previous report showed ‪−3.67 M‬ USD of net income which accounts for −130.50% change. Track more Paradigm Biopharmaceuticals Ltd. financial stats to get the full picture.
No, PBIGF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Paradigm Biopharmaceuticals Ltd. EBITDA is ‪−15.02 M‬ USD, and current EBITDA margin is ‪−43.81 K‬%. See more stats in Paradigm Biopharmaceuticals Ltd. financial statements.
Like other stocks, PBIGF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Paradigm Biopharmaceuticals Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Paradigm Biopharmaceuticals Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Paradigm Biopharmaceuticals Ltd. stock shows the sell signal. See more of Paradigm Biopharmaceuticals Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.